Immuneering Corp (IMRX)
2.00
-0.36
(-15.25%)
USD |
NASDAQ |
Jan 08, 16:00
1.99
-0.01
(-0.50%)
After-Hours: 20:00
Immuneering SG&A Expense (Quarterly): 4.014M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 75.11M |
| PTC Therapeutics Inc | 73.46M |
| Aadi Bioscience Inc | 7.186M |
| AN2 Therapeutics Inc | 3.484M |
| NovaBay Pharmaceuticals Inc | 2.65M |